The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Over the past year, Editas Medicine (EDIT 13.78%) and Sarepta Therapeutics (SRPT 2.74%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market ...

Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The announcement of a safety update for ELEVIDYS, concerning severe side effects and ...

SAN DIEGO, June 26, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and ...

Sarepta’s stock fell an additional 8% in response, according to the Complaint. Please visit our website to review more information and submit your transaction information.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ: SRPT), presenting a wide array of perspectives from bullish to bearish. The table below provides ...

Both patients were teenage boys who passed away after developing acute liver failure within two months after treatment with Sarepta’s one-time therapy.

IFS officer Parveen Kaswan said she raised cubs that helped repopulate parts of Ranthambhore and other tiger reserves, and carried bloodline of Ranthambore.

In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. Both boys were non-ambulatory ...